News | October 24, 2011

Study Links Birth Defects to High Blood Pressure, Not ACE Inhibitors

October 24, 2011 — A new study demonstrates that angiotensin-converting enzyme (ACE) inhibitors taken in the first trimester of pregnancy pose no greater risk of birth defects than any other type of high blood pressure medication. The study, conducted by the U.S. Department of Health and Human Services’ (HHS) Agency for Healthcare Research and Quality (AHRQ), suggests high blood pressure itself may increase the risk of birth defects.

ACE inhibitors are among the most widely prescribed drugs used to treat high blood pressure, particularly for people who also have diabetes. They are known to raise the rate of birth defects in the second and third trimesters of pregnancy; one earlier study reported a link between their use and birth defects in the first trimester of pregnancy.

But the new AHRQ report, based on a study of a larger population, did not find a unique link between first-trimester ACE inhibitor use and birth defects.  

Results of the study, prepared for AHRQ's Effective Health Care Program by the HMO Research Network — a member of AHRQ's Developing Evidence to Improve Decisions about Effectiveness (DEcIDE) Network — are published in the Oct. 18 issue of the British Medical Journal.  

"Some women of child-bearing age have high blood pressure, and about half of them will get pregnant while taking one or more medications to treat it," said AHRQ Director Carolyn M. Clancy, M.D. "This report should lead to more informed discussions by women, in consultation with their doctors, about the best way to manage their high blood pressure, particularly if they become pregnant."

ACE inhibitors are also used to treat heart failure and to protect some people from diabetes complications. Yet because they inhibit an enzyme in the kidney, physicians caution use in the second and third trimesters of pregnancy, a crucial period of development for the unborn baby.

The drugs carry a "black box" warning from the U.S. Food and Drug Administration (FDA) — that agency's strongest warning — against their use in the second and third trimesters of pregnancy.

A study published in 2006 examined nearly 30,000 births over 15 years to mothers enrolled in Tennessee's Medicaid system; it suggested pregnant women who took ACE inhibitors in the first trimester had babies with birth defects at approximately three times the rate of mothers who not taking blood pressure medicine.

But the new AHRQ study — which examined more than 465,000 babies born over 13 years in the Kaiser Permanente Northern California region — found no such correlation. It found birth defects occurred at the same rate among all women with high blood pressure, regardless of whether they took ACE inhibitors, other blood pressure drugs or none at all.

While the AHRQ study did not conclude high blood pressure is explicitly to blame for increased birth defects, researchers said the findings suggest it is likely. Thus, taking steps to reduce blood pressure before pregnancy — including losing weight and reducing sodium intake — may reduce the risk of birth defects.

For more information on blood pressure visit

For more information:

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init